207 related articles for article (PubMed ID: 30099911)
1. Cardiovascular impact of testosterone therapy for hypogonadism.
Rastrelli G; Dicuio M; Reismann Y; Sforza A; Maggi M; Corona G
Expert Rev Cardiovasc Ther; 2018 Sep; 16(9):617-625. PubMed ID: 30099911
[TBL] [Abstract][Full Text] [Related]
2. Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies.
Corona G; Rastrelli G; Di Pasquale G; Sforza A; Mannucci E; Maggi M
J Sex Med; 2018 Jun; 15(6):820-838. PubMed ID: 29803351
[TBL] [Abstract][Full Text] [Related]
3. [Testosterone replacement therapy and cardiovascular risk].
Corona G; Dicuio M; Rastrelli G; Sforza A; Maggi M
G Ital Cardiol (Rome); 2017 Nov; 18(11):745-753. PubMed ID: 29105668
[TBL] [Abstract][Full Text] [Related]
4. Testosterone treatment and cardiovascular and venous thromboembolism risk: what is 'new'?
Corona G; Dicuio M; Rastrelli G; Maseroli E; Lotti F; Sforza A; Maggi M
J Investig Med; 2017 Aug; 65(6):964-973. PubMed ID: 28495861
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis.
Corona G; Maseroli E; Rastrelli G; Isidori AM; Sforza A; Mannucci E; Maggi M
Expert Opin Drug Saf; 2014 Oct; 13(10):1327-51. PubMed ID: 25139126
[TBL] [Abstract][Full Text] [Related]
6. The safety of available treatments of male hypogonadism in organic and functional hypogonadism.
Corona G; Rastrelli G; Reisman Y; Sforza A; Maggi M
Expert Opin Drug Saf; 2018 Mar; 17(3):277-292. PubMed ID: 29334271
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality.
Saad F; Caliber M; Doros G; Haider KS; Haider A
Aging Male; 2020 Mar; 23(1):81-92. PubMed ID: 30782054
[No Abstract] [Full Text] [Related]
8. Pharmacological management of late-onset hypogonadism.
Rastrelli G; Maggi M; Corona G
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):439-458. PubMed ID: 29505313
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome.
Hackett G
Sex Med Rev; 2019 Jul; 7(3):476-490. PubMed ID: 30803918
[TBL] [Abstract][Full Text] [Related]
10. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.
Haider A; Yassin A; Haider KS; Doros G; Saad F; Rosano GM
Vasc Health Risk Manag; 2016; 12():251-61. PubMed ID: 27366080
[TBL] [Abstract][Full Text] [Related]
11. Hypogonadism: Therapeutic Risks, Benefits, and Outcomes.
Sigalos JT; Pastuszak AW; Khera M
Med Clin North Am; 2018 Mar; 102(2):361-372. PubMed ID: 29406064
[TBL] [Abstract][Full Text] [Related]
12. Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism.
Grabner M; Hepp Z; Raval A; Tian F; Khera M
J Sex Med; 2018 Feb; 15(2):148-158. PubMed ID: 29425664
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups.
Traish AM; Haider A; Haider KS; Doros G; Saad F
J Cardiovasc Pharmacol Ther; 2017 Sep; 22(5):414-433. PubMed ID: 28421834
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.
Corona G; Rastrelli G; Morgentaler A; Sforza A; Mannucci E; Maggi M
Eur Urol; 2017 Dec; 72(6):1000-1011. PubMed ID: 28434676
[TBL] [Abstract][Full Text] [Related]
15. The state of testosterone therapy since the FDA's 2015 labelling changes: Indications and cardiovascular risk.
Miner M; Morgentaler A; Khera M; Traish AM
Clin Endocrinol (Oxf); 2018 Jul; 89(1):3-10. PubMed ID: 29486065
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular safety of testosterone replacement therapy in men: an updated systematic review and meta-analysis.
Corona G; Rastrelli G; Sparano C; Carinci V; Casella G; Vignozzi L; Sforza A; Maggi M
Expert Opin Drug Saf; 2024 May; 23(5):565-579. PubMed ID: 38553429
[TBL] [Abstract][Full Text] [Related]
17. Alternatives to Testosterone Therapy: A Review.
Lo EM; Rodriguez KM; Pastuszak AW; Khera M
Sex Med Rev; 2018 Jan; 6(1):106-113. PubMed ID: 29174957
[TBL] [Abstract][Full Text] [Related]
18. Testosterone Replacement Therapy: Long-Term Safety and Efficacy.
Corona G; Sforza A; Maggi M
World J Mens Health; 2017 Aug; 35(2):65-76. PubMed ID: 28497912
[TBL] [Abstract][Full Text] [Related]
19. Hypotestosteronaemia in the aging male: should we treat it?
Christe N; Meier CA
Swiss Med Wkly; 2015; 145():w14216. PubMed ID: 26599486
[TBL] [Abstract][Full Text] [Related]
20. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study.
Corona G; Rastrelli G; Monami M; Guay A; Buvat J; Sforza A; Forti G; Mannucci E; Maggi M
Eur J Endocrinol; 2011 Nov; 165(5):687-701. PubMed ID: 21852391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
